Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

NCT06108414 is registered in ClinicalTrials.gov with China National Center for Cardiovascular Diseases as lead sponsor.

NCT NCT06108414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06108414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
Lead sponsor
China National Center for Cardiovascular Diseases
Phase
Phase 4
Overall status
Recruiting
Start date
September 1, 2024
Completion date
December 31, 2027
Enrollment
4,374 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulant adverse reaction, atrial fibrillation, major adverse cardiac events, stroke